Blog
RSS FeedPosted by Michael Wonder on 29 Jun 2020
Successful Eloctaq bid should widen access to the drug in the UK
29 June 2020 - The NHS and Sobi UK have come to an agreement that will give people living with ...
Posted by Michael Wonder on 08 May 2020
HyQvia gets a higher price
8 May 2020 - HyQvia 100 mg/mL solution for injection contains human immunoglobulin, which is an antibody used to strengthen ...
Posted by Michael Wonder on 07 May 2020
CSL Behring Australia commences development of treatment for serious cases of COVID-19
6 May 2020 - Plasma-derived therapeutic with potential to treat serious complications of COVID-19. ...
Posted by Michael Wonder on 06 May 2020
COVID-19: potentially life saving immunoglobulin treatment for seriously ill Australians
6 May 2020 - The Australian Government welcomes the announcement by CSL Behring that Australia will be one of the first ...
Posted by Michael Wonder on 06 May 2020
CSL ramps up development of COVID-19 plasma treatment
6 May 2020 - Australia’s biggest health company CSL has confirmed it will immediately begin development of plasma-derived therapy to ...
Posted by Michael Wonder on 03 May 2020
Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with Ruconest
30 April 2020 - European Commission decision was received six weeks earlier than expected. ...
Posted by Michael Wonder on 25 Apr 2020
CSL's blood payments in US under the microscope
25 April 2020 - CSL has been forced to defend the way it runs its blood plasma collection business in ...
Posted by Michael Wonder on 21 Apr 2020
Andexanet alfa for reversing anticoagulation
21 April 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using andexanet alfa ...
Posted by Michael Wonder on 08 Apr 2020
Cows come home for CSL in COVID-19 vaccine battle
8 April 2020 - It sounds like a pitch for a sci-fi thriller — using genetically modified cows to fight ...
Posted by Michael Wonder on 07 Apr 2020
Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...
Posted by Michael Wonder on 01 Apr 2020
FDA approves additional treatment for adults and adolescents with haemophilia A or B and inhibitors
1 April 2020 - The U.S. FDA today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding ...
Posted by Michael Wonder on 28 Jan 2020
TLV is reviewing the subsidy of factor VIII drugs with side agreements
28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves ...
Posted by Michael Wonder on 06 Nov 2019
Octapharma’s fibryga receives European label extension to treat acquired fibrinogen deficiency (AFD)
5 November 2019 - Octapharma announced today that the human fibrinogen concentrate fibryga has received approval for use in treatment of ...
Posted by Michael Wonder on 05 Nov 2019
A severe shortage hits a drug used for cancer, immune disorders, epilepsy, causing canceled treatments and rationing
5 November 2019 - A severe shortage of immune globulin — a popular medicine used to treat epilepsy, cancer and ...
Posted by Michael Wonder on 08 Oct 2019
FDA approves Octapharma’s Wilate for haemophilia A in adult and adolescent patients
8 October 2019 - Octapharma USA today announced the U.S. FDA has approved Wilate for treatment of adults and adolescents with ...